Who are SYR-322-MET's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Byetta (Exenatide), Semaglutide Pen Injector [Ozempic], Exenatide twice daily (BID), Lixisenatide (AVE0010), Victoza (liraglutide), Semaglutide Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/syr-322-met.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

SYR-322-MET — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SYR-322-MET (SYR-322-MET) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Diabetes.

phase 3 GLP-1 receptor agonist GLP-1R Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

SYR-322-MET (SYR-322-MET) — Takeda. SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SYR-322-MET TARGET	SYR-322-MET	Takeda	phase 3	GLP-1 receptor agonist	GLP-1R
Byetta (Exenatide)	Byetta (Exenatide)	Beijing Chao Yang Hospital	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide Pen Injector [Ozempic]	Semaglutide Pen Injector [Ozempic]	University of Nottingham	marketed	GLP-1 receptor agonist	GLP-1R
Exenatide twice daily (BID)	Exenatide twice daily (BID)	Eli Lilly and Company	marketed	GLP-1 receptor agonist	GLP-1R
Lixisenatide (AVE0010)	Lixisenatide (AVE0010)	Sanofi	marketed	GLP-1 receptor agonist	GLP-1R
Victoza (liraglutide)	Victoza (liraglutide)	Zealand University Hospital	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide Injectable Product	Semaglutide Injectable Product	Neurogastrx, Inc.	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

2026-03-26 — Semaglutide Injectable Product · EMA · approved · EU · Neurogastrx, Inc.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SYR-322-MET — Competitive Intelligence Brief. https://druglandscape.com/ci/syr-322-met. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab